380 related articles for article (PubMed ID: 17116003)
1. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.
Lundåsen T; Gälman C; Angelin B; Rudling M
J Intern Med; 2006 Dec; 260(6):530-6. PubMed ID: 17116003
[TBL] [Abstract][Full Text] [Related]
2. Asynchronous rhythms of circulating conjugated and unconjugated bile acids in the modulation of human metabolism.
Al-Khaifi A; Straniero S; Voronova V; Chernikova D; Sokolov V; Kumar C; Angelin B; Rudling M
J Intern Med; 2018 Nov; 284(5):546-559. PubMed ID: 29964306
[TBL] [Abstract][Full Text] [Related]
3. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers.
Al-Khaifi A; Rudling M; Angelin B
Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896
[TBL] [Abstract][Full Text] [Related]
4. Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19.
Barrera F; Azócar L; Molina H; Schalper KA; Ocares M; Liberona J; Villarroel L; Pimentel F; Pérez-Ayuso RM; Nervi F; Groen AK; Miquel JF
Ann Hepatol; 2015; 14(5):710-21. PubMed ID: 26256900
[TBL] [Abstract][Full Text] [Related]
5. Chenodeoxycholic Acid Modulates Bile Acid Synthesis Independent of Fibroblast Growth Factor 19 in Primary Human Hepatocytes.
Johansson H; Søndergaard JN; Jorns C; Kutter C; Ellis ECS
Front Endocrinol (Lausanne); 2020; 11():554922. PubMed ID: 33692750
[TBL] [Abstract][Full Text] [Related]
6. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
Friedrich D; Marschall HU; Lammert F
BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
[TBL] [Abstract][Full Text] [Related]
7. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19.
Gälman C; Angelin B; Rudling M
J Intern Med; 2011 Dec; 270(6):580-8. PubMed ID: 22003820
[TBL] [Abstract][Full Text] [Related]
8. Diurnal variations of mouse plasma and hepatic bile acid concentrations as well as expression of biosynthetic enzymes and transporters.
Zhang YK; Guo GL; Klaassen CD
PLoS One; 2011 Feb; 6(2):e16683. PubMed ID: 21346810
[TBL] [Abstract][Full Text] [Related]
9. A nontumorigenic variant of FGF19 treats cholestatic liver diseases.
Luo J; Ko B; Elliott M; Zhou M; Lindhout DA; Phung V; To C; Learned RM; Tian H; DePaoli AM; Ling L
Sci Transl Med; 2014 Jul; 6(247):247ra100. PubMed ID: 25080475
[TBL] [Abstract][Full Text] [Related]
10. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis.
Li Z; Lin B; Lin G; Wu Y; Jie Y; Li X; Ko B; Chong Y; Luo J
PLoS One; 2017; 12(6):e0178580. PubMed ID: 28570655
[TBL] [Abstract][Full Text] [Related]
11. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.
Schaap FG; van der Gaag NA; Gouma DJ; Jansen PL
Hepatology; 2009 Apr; 49(4):1228-35. PubMed ID: 19185005
[TBL] [Abstract][Full Text] [Related]
12. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass.
Gerhard GS; Styer AM; Wood GC; Roesch SL; Petrick AT; Gabrielsen J; Strodel WE; Still CD; Argyropoulos G
Diabetes Care; 2013 Jul; 36(7):1859-64. PubMed ID: 23801799
[TBL] [Abstract][Full Text] [Related]
13. Exercise training and diet-induced weight loss increase markers of hepatic bile acid (BA) synthesis and reduce serum total BA concentrations in obese women.
Mercer KE; Maurer A; Pack LM; Ono-Moore K; Spray BJ; Campbell C; Chandler CJ; Burnett D; Souza E; Casazza G; Keim N; Newman J; Hunter G; Fernadez J; Garvey WT; Harper ME; Hoppel C; Adams SH; Thyfault J
Am J Physiol Endocrinol Metab; 2021 May; 320(5):E864-E873. PubMed ID: 33645254
[TBL] [Abstract][Full Text] [Related]
14. Regulation of diurnal variation of cholesterol 7alpha-hydroxylase (CYP7A1) activity in healthy subjects.
Kovář J; Leníček M; Zimolová M; Vítek L; Jirsa M; Pitha J
Physiol Res; 2010; 59(2):233-238. PubMed ID: 19537927
[TBL] [Abstract][Full Text] [Related]
15. Regulation of bile acid metabolism in biliary atresia: reduction of FGF19 by Kasai portoenterostomy and possible relation to early outcome.
Johansson H; Svensson JF; Almström M; Van Hul N; Rudling M; Angelin B; Nowak G; Fischler B; Ellis E
J Intern Med; 2020 May; 287(5):534-545. PubMed ID: 31976601
[TBL] [Abstract][Full Text] [Related]
16. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease.
Wunsch E; Milkiewicz M; Wasik U; Trottier J; Kempińska-Podhorodecka A; Elias E; Barbier O; Milkiewicz P
Sci Rep; 2015 Aug; 5():13462. PubMed ID: 26293907
[TBL] [Abstract][Full Text] [Related]
17. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study.
Uriarte I; Santamaria E; López-Pascual A; Monte MJ; Argemí J; Latasa MU; Adán-Villaescusa E; Irigaray A; Herranz JM; Arechederra M; Basualdo J; Lucena F; Corrales FJ; Rotellar F; Pardo F; Merlen G; Rainteau D; Sangro B; Tordjmann T; Berasain C; Marín JJG; Fernández-Barrena MG; Herrero I; Avila MA
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167166. PubMed ID: 38642480
[TBL] [Abstract][Full Text] [Related]
18. Developmental regulation of the gut-liver (FGF19-CYP7A1) axis in neonates.
Memon N; Griffin IJ; Lee CW; Herdt A; Weinberger BI; Hegyi T; Carayannopoulos MO; Aleksunes LM; Guo GL
J Matern Fetal Neonatal Med; 2020 Mar; 33(6):987-992. PubMed ID: 30122083
[No Abstract] [Full Text] [Related]
19. Acute caloric restriction counteracts hepatic bile acid and cholesterol deficiency in morbid obesity.
Straniero S; Rosqvist F; Edholm D; Ahlström H; Kullberg J; Sundbom M; Risérus U; Rudling M
J Intern Med; 2017 May; 281(5):507-517. PubMed ID: 28261926
[TBL] [Abstract][Full Text] [Related]
20. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
Schreuder TC; Marsman HA; Lenicek M; van Werven JR; Nederveen AJ; Jansen PL; Schaap FG
Am J Physiol Gastrointest Liver Physiol; 2010 Mar; 298(3):G440-5. PubMed ID: 20093562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
